Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, Kraus G, Picchio G, de Béthune MP.

Antivir Ther. 2009;14(1):103-9.

PMID:
19320243
2.

[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

Arazo Garcés P, Omiste Sanvicente T.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:23-31. Review. Spanish.

PMID:
19195456
3.

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F.

J Antimicrob Chemother. 2009 Mar;63(3):585-92. doi: 10.1093/jac/dkn544.

PMID:
19147519
4.

Update of the Drug Resistance Mutations in HIV-1.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2008 Dec;16(5):138-45. Review. Erratum in: Top HIV Med. 2009 Feb-Mar;17(1):13.

5.

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.

Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08.

6.

Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.

Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, Ceresoli F, Gargiulo F, Manca N, Carosi G, Torti C.

Antivir Ther. 2008;13(4):601-5.

PMID:
18672539
7.

Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.

Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, Paredes R, Clotet B.

J Antimicrob Chemother. 2008 Nov;62(5):909-13. doi: 10.1093/jac/dkn297.

PMID:
18653487
8.

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V.

Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. doi: 10.1128/AAC.00133-08.

9.

Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.

Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group..

J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127.

PMID:
18390885
10.

Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

Poveda E, Garrido C, de Mendoza C, Corral A, Cobo J, González-Lahoz J, Soriano V.

J Antimicrob Chemother. 2007 Dec;60(6):1409-10. No abstract available.

PMID:
17913723
11.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group..

Lancet. 2007 Jul 7;370(9581):39-48.

PMID:
17617271
12.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group..

Lancet. 2007 Jul 7;370(9581):29-38.

PMID:
17617270
13.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

TMC125-C223 Writing Group., Nadler JP, Berger DS, Blick G, Cimoch PJ, Cohen CJ, Greenberg RN, Hicks CB, Hoetelmans RM, Iveson KJ, Jayaweera DS, Mills AM, Peeters MP, Ruane PJ, Shalit P, Schrader SR, Smith SM, Steinhart CR, Thompson M, Vingerhoets JH, Voorspoels E, Ward D, Woodfall B.

AIDS. 2007 Mar 30;21(6):F1-10.

PMID:
17413684
14.

Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance.

Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D.

J Med Virol. 2006 Feb;78(2):153-60.

PMID:
16372300
15.

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.

Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Béthune MP.

J Virol. 2005 Oct;79(20):12773-82.

17.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP.

Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6.

18.

Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Béthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E.

J Med Chem. 2004 May 6;47(10):2550-60.

PMID:
15115397
19.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group..

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
20.

Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.

Udier-Blagović M, Tirado-Rives J, Jorgensen WL.

J Am Chem Soc. 2003 May 21;125(20):6016-7.

PMID:
12785806
Items per page

Supplemental Content

Support Center